Prediction of recurrence for bladder cancer by a protein signature in tissue samples

Abstract

The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.

1 - 15 . (canceled) 
     
     
         16 . A method for predicting the risk of recurrence of bladder cancer in a subject, comprising the steps of:
 (a) determining the amount of at least one biomarker selected from the biomarkers shown in Table 1 in a sample from the subject; and   (a) comparing the amount of the at least one biomarker with a reference amount for the at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted.   
     
     
         17 . The method of  claim 16 , wherein the at least one biomarker is selected from the group of biomarkers listed in Table 2, and wherein an increase in the at least one biomarker as compared to the reference amount indicates that the subject is at risk of recurrence of bladder cancer. 
     
     
         18 . The method of  claim 16 , wherein the at least one biomarker is selected from the group of biomarkers listed in Table 3, and wherein a decrease in the at least one biomarker as compared to the reference amount indicates that the subject is at risk of recurrence of bladder cancer. 
     
     
         19 . The method of  claim 16 , wherein the risk of recurrence of bladder cancer is predicted after surgery comprising removal of a tumor. 
     
     
         20 . The method of  claim 19 , wherein the surgery is transurethral resection, or radical cystectomy, or partial cystectomy. 
     
     
         21 . The method of  claim 16 , wherein the sample is tumor tissue, or a blood, serum or plasma sample. 
     
     
         22 . The method of  claim 16 , wherein the reference amount is derived from a subject or group of subjects known to be at risk for recurrence of bladder cancer, or from a subject or group of subjects known to not be at risk for recurrence of bladder cancer. 
     
     
         23 . A method for identifying a subject in need of a further bladder cancer therapy after treatment of bladder cancer, comprising the steps of:
 (a) determining the amount of at least one biomarker selected from the biomarkers shown in Table 1 in a sample of a subject; and   (b) comparing the amount of the at least one biomarker with a reference amount for the at least one biomarker, whereby a subject in need of further bladder cancer therapy is to be identified.   
     
     
         24 . The method of  claim 23 , wherein the treatment of bladder cancer is surgery comprising removal of a tumor, and/or wherein the further bladder cancer therapy is adjuvant intravesical therapy. 
     
     
         25 . A method for predicting the risk of progression of bladder cancer in a subject suffering from bladder cancer, comprising the steps of:
 (a) determining the amount of at least one biomarker selected from the biomarkers shown in Table 1 in a sample from the subject; and   (b) comparing the amount of the at least one biomarker with a reference amount for the at least one biomarker, whereby the risk of progression of bladder cancer is to be predicted.